The PCT international phase is only the starting cost. Translation, official fees, local counsel and annuities make the national phase the larger expense. Three decision points can help control the budget.
The short answer
A PCT international patent application costs money in two stages. The international phase, including official and attorney fees, is the entry ticket. The national phase brings translation, official fees and local counsel in every jurisdiction entered, so costs scale roughly with the number of countries. Three checkpoints help control costs: use the international search opinion to make decisions, prune the country list within the 30-month window, and slim the claims before entry.
Where does the money go?
International phase. The main official fees are WIPO's international filing fee, including surcharges for pages beyond 30, and the International Searching Authority's search fee. Together with attorney fees, this stage typically runs in the low-to-mid four figures in US dollars for a straightforward case. It provides an international filing date across more than 150 contracting states and time to decide where protection is worth pursuing.
National phase. Entry is generally due within 30 months from the priority date, or 31 months in some jurisdictions, including the EPO and Korea. Each entry brings translation into the required language, national official fees such as filing, examination, excess claim and page fees, and local associate fees. Annuities may rise over time; in some jurisdictions, including Europe and Australia, relevant annual fees are due before grant.
Most lifetime costs of a PCT-route patent application arise during national phase entry and subsequent maintenance. The answer to 'how much?' depends on how many jurisdictions you enter. Check each deadline against WIPO's PCT Time Limits page: https://www.wipo.int/en/web/pct-system/texts/time_limits.
Checkpoint 1: Use the international search opinion to decide
A PCT application receives an International Search Report (ISR) and a Written Opinion assessing novelty, inventive step and industrial applicability. These findings do not bind national examiners, but they provide an early assessment before national phase spending begins.
First, make a go/no-go decision. If the Written Opinion is negative on every claim and no credible response appears available, consider whether national phase entry is justified. Stopping at this stage avoids downstream costs in every jurisdiction.
Second, address common issues internationally. Article 19 permits claim amendments after the ISR. A Chapter II demand enables Article 34 amendments and leads to an International Preliminary Examination Report. A well-judged amendment at this stage may reduce repeated work when similar objections arise in several national proceedings.
Third, calibrate the country list. Positive findings on the independent claims may support broader entry. If only narrow dependent claims receive positive findings, shorten the list and review the independent claims before entering.
Checkpoint 2: Prune countries within the 30-month window
The value of the decision window is the information gained over time. More than two years after the priority date, market traction, customer locations and competitor moves are clearer. Before entering, ask: Will this country see real sales or channel activity within three years? Do key competitors file or manufacture there? Is the enforcement environment worth the costs of grant and maintenance?
For a borderline jurisdiction, choosing not to enter avoids the full chain of translation, official fees, associate fees and annuities. Part 3 of this series covers the five-dimension country selection framework; Part 5 covers portfolio-level budget allocation.
Checkpoint 3: Tailor claim counts before entry
Major offices often charge fees based on claim count. The EPO charges for claims from the 16th onward, in escalating bands. The USPTO charges excess claim fees above 20 total or three independent claims. In Japan and Korea, examination fees depend on the number of claims, which can also affect post-grant annuities.
A claim set drafted for multiple jurisdictions can generate repeated fees if filed unchanged everywhere. Tailor the entry instructions to each office: combine dependent claims, remove claim categories that the office does not accept or the applicant does not intend to assert, and manage claim counts with local fee rules in mind. Keep support in the specification so that, where available, divisionals or US continuation practice can preserve future options.
PCT versus the Paris Convention route
Decision window: PCT national phase entry is generally due 30 months from the priority date, or 31 months in some offices. Direct Paris Convention filings are generally due within 12 months from the priority date.
Upfront cost: the PCT route adds international phase fees before national costs. The Paris route pays the target-country filing costs directly, without an international phase.
Search feedback and timing: the PCT route supplies an ISR and Written Opinion before national phase spending, although national examination usually starts after entry. The Paris route has no unified international assessment, but national examination may begin earlier.
With only one or two certain target countries, direct Paris Convention filings usually cost less overall. When the target countries remain uncertain or numerous, the PCT decision window and the opportunity to address common issues can justify its international phase cost. Subject to the applicable rules, the routes can also be combined for the same priority: direct filings in confirmed core markets and a PCT application for markets still under consideration.
Fee reductions worth checking
Check the rules in force when filing. WIPO offers international filing fee reductions for qualifying natural-person applicants; corporate applicants generally do not qualify. CNIPA's fee reduction scheme lowers certain official fees for eligible applicants, and some Chinese local governments support PCT filings and foreign grants. Local programmes may change. Filing decisions should be based on technical and market value, with subsidies treated as a cost improvement.
Frequently asked questions
Q1: Can international phase costs be reduced? To some extent: control page count, choose the searching authority deliberately, and check WIPO fee reduction eligibility for natural persons. The larger savings usually come from national phase selection.
Q2: Should a negative Written Opinion end the application? Not automatically. It binds no national examiner, and objections may be arguable or fixable by amendment. Use it to assess risk and choose a more conservative country list where appropriate.
Q3: Can the 30-month deadline be extended? The 30- or 31-month limits depend on national law and generally cannot be extended in advance. Some jurisdictions permit restoration after a missed deadline, but the requirements are demanding and the remedy is not universal. Use reconciled deadline records.
Q4: How should a company rank countries on a tight budget? Start with primary sales markets, competitors' home jurisdictions and manufacturing locations, then adjust for enforcement environment and cost. Part 3 covers the full five-dimension framework; Part 5 covers budget allocation across multiple applications.
About this series
This is Part 2 of 6 in WISPRO's IP Strategy for Companies Going Global series. It is published by Suzhou Wispro Intellectual Property Agency (Agency Code 32235) and Wispro Innovation and Intellectual Property Consulting (Suzhou) Inc.